+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Drug Overview: QVM149

  • PDF Icon


  • 15 Pages
  • February 2018
  • Region: Global
  • Citeline
  • ID: 4533479
Drug Overview

QVM149 (Novartis) is a fixed triple combination product consisting of a long-acting muscarinic antagonist (glycopyrronium bromide), a long-acting beta 2 agonist (LABA) (indacaterol), and an inhaled corticosteroid (ICS) (mometasone furoate). QVM149 is in Phase III development for the treatment of moderate to severe asthma uncontrolled with standard ICS/LABA therapies.

Table of Contents

Product Profiles
QVM149: Asthma

List of Figures
Figure 55: Spiriva sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26
Figure 56: Symbicort for asthma - SWOT analysis
List of Tables
Table 1: QVM149 drug profile
Table 2: QVM149 Phase III trials in asthma
Table 3: QVM149 sales for asthma across Japan and the five major EU markets, by country ($m), 2017-26